Discover
PLRZ
Polyrizon Ltd.
12.68
2 x 9.02
2 x 15.36
bid
ask
+
0.16
1.28%
2 @ 04:00 PM
12.75 +0.07 (0.52%)
| Ytd | 49.35% | |
| 1y | 192.17% |
12.24
day range
12.96
2.88
52 week range
18.20
| Open | 12.38 | Prev Close | 12.52 | Low | 12.24 | High | 12.96 | Mkt Cap | 26.42M |
| Vol | 16.32K | Avg Vol | 44.46K | EPS | -4.90 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | 0.08 | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 13.95 | 200-d Avg | 11.06 | 1yr Est | 0.00 |
PLRZ News
benzinga.com
Polyrizon Receives Central IRB Approval To Begin First Human Clinical Trial For NASARIX, Nasal Spray
Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage bio
globenewswire.com
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Tria
Raanana, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “
benzinga.com
Polyrizon Launches Human Study With Top European Medical Center To Validate NASARIX Allergy Blocker'
New performance and characterization study in collaboration with leading European medical center mar
benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
Polyrizon Announces European Patent Office To Publish The Company's Application 'Mucoadhesive Polyme
The application was published under European publication number EP 4751737. The patent application c
benzinga.com
Polyrizon Signs Agreements With Two Additional U.S. Clinical Sites For Nasarix PL-14 Clinical Study
The study, titled "Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker
benzinga.com
Polyrizon Ltd. Extends Exclusivity Period For Proposed 51% Acquisition Of Arrow Aviation Through Jun
As previously announced, on February 4, 2026, Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company") a